Skip to content
Search

Latest Stories

The deadline for the 2023 mandatory workforce survey closes in a week

The survey aims to provide a comprehensive picture of the community pharmacy workforce

Pharmacy owners have less than a week to complete the mandatory 2023 Community Pharmacy Workforce Survey, which closes on Sunday, December 17.


The NHS Business Services Authority sent an email with a survey link to pharmacy owners on October 23, 2023. In certain cases, such as Company Chemists’ Association member companies and other multiple pharmacy groups, head offices will centrally complete the survey.

“If you're unsure whether the survey will be completed centrally, please seek guidance from your head office,” Community Pharmacy England has said.

Since 2022, completing the annual NHS England community pharmacy workforce survey has been a Terms of Service requirement for pharmacy owners.

The survey, conducted by the North of England Commissioning Support Unit (NECS) on behalf of NHS England, includes questions about staff numbers and full-time equivalents (FTEs) for various roles, such as pharmacists, trainee pharmacists, pharmacy technicians, dispensing assistants, medicines counter assistants, and delivery drivers.

The survey also asks about any trainees in the pharmacy.

The data aims to provide a comprehensive picture of the community pharmacy workforce, identifying vacancies and regions that are particularly challenging to fill, CPE added.

This information will support decisions on how the community pharmacy workforce can contribute to clinical service expansion and ensure that education reforms benefit both pharmacists and pharmacy technicians, enabling patients to receive more services from their community pharmacies.

Data from the 2023 survey, along with the principles used for data cleansing, will be available on Community Pharmacy Workforce Survey – data.gov.uk in 2024.

The 2022 Community Pharmacy Workforce Survey revealed a 6 per cent decrease in the community pharmacy workforce, with a notable drop of 2,411 full-time equivalent pharmacists from 2021 to 2022, settling at 17,844.

Employed pharmacists decreased by 16 per cent, from 12,774 in 2021 to 10,943 in 2022, while locum pharmacists increased by 26 per cent, rising from 4,297 in 2021 to 5,477 in 2022.

Despite these changes, the total headcount of community pharmacists remained 'almost constant' between 2021 and 2022, indicating a trend of pharmacists working fewer hours in a community setting.

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less